Have a feature idea you'd love to see implemented?
Let us know!
NRBO NeuroBo Pharmaceuticals Inc
Price (delayed)
$2.35
Market cap
$20.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.74
Enterprise value
-$1.27M
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The
Highlights
The debt fell by 29% YoY and by 9% QoQ
The EPS has shrunk by 112% YoY but it has increased by 4% QoQ
The company's net income has shrunk by 134% YoY and by 7% QoQ
The quick ratio has dropped by 56% year-on-year and by 17% since the previous quarter
Key stats
What are the main financial stats of NRBO
Market
Valuations
Earnings
Shares outstanding
8.62M
Market cap
$20.25M
Enterprise value
-$1.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$27.73M
EBITDA
-$27.71M
Free cash flow
-$22.69M
Per share
Balance sheet
Liquidity
EPS
-$4.74
Free cash flow per share
-$2.22
Book value per share
$1.53
Revenue per share
$0
TBVPS
$2.17
Total assets
$22.15M
Total liabilities
$9.19M
Debt
$154,000
Equity
$12.95M
Working capital
$12.82M
Debt to equity
0.01
Current ratio
2.41
Quick ratio
2.38
Net debt/EBITDA
0.78
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-122.3%
Return on equity
-189.1%
Return on invested capital
N/A
Return on capital employed
-212.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRBO stock price
How has the NeuroBo Pharmaceuticals stock price performed over time
Intraday
-2.08%
1 week
-1.67%
1 month
-19.52%
1 year
-31.69%
YTD
-36.49%
QTD
-25.87%
Financial performance
How have NeuroBo Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.89M
Net income
-$27.73M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 134% YoY and by 7% QoQ
NRBO's operating income is down by 40% YoY and by 9% from the previous quarter
Growth
What is NeuroBo Pharmaceuticals's growth rate over time
Valuation
What is NeuroBo Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 112% YoY but it has increased by 4% QoQ
The P/B is 71% below the 5-year quarterly average of 5.2 and 4.4% below the last 4 quarters average of 1.6
The equity has declined by 40% year-on-year and by 32% since the previous quarter
Efficiency
How efficient is NeuroBo Pharmaceuticals business performance
The ROE fell by 23% QoQ
The ROA has contracted by 12% from the previous quarter
Dividends
What is NRBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRBO.
Financial health
How did NeuroBo Pharmaceuticals financials performed over time
NeuroBo Pharmaceuticals's total assets is 141% higher than its total liabilities
The total liabilities has surged by 89% year-on-year but it has declined by 6% since the previous quarter
NeuroBo Pharmaceuticals's current ratio has plunged by 56% YoY and by 18% from the previous quarter
The debt is 99% lower than the equity
The equity has declined by 40% year-on-year and by 32% since the previous quarter
The debt fell by 29% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.